Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Mainz Biomed N.V. - Ordinary Shares (NQ: MYNZ ) 0.2460 +0.0321 (+15.01%) Streaming Delayed Price Updated: 2:58 PM EDT, Sep 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Mainz Biomed N.V. - Ordinary Shares < Previous 1 2 3 4 5 6 7 8 9 Next > 12 Health Care Stocks Moving In Friday's Intraday Session Today 12:31 EDT Via Benzinga Pfizer Advances On Its Cancer Journey September 20, 2024 On Saturday, Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer cachexia during the European Society for Medical Oncology 2024... Via Benzinga Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador September 18, 2024 Strategic Alliance with Former White House Senior Adviser to Focus on Awareness of Mainz Biomed’s Products and the Importance of Early Detection From Mainz BioMed NV Via GlobeNewswire Mainz Biomed (NASDAQ: MYNZ) And Liquid Biosciences Team Up To Fight Pancreatic Cancer With Early Detection Tool September 05, 2024 Mainz Biomed (NASDAQ: MYNZ) And Liquid Biosciences Team Up To Fight Pancreatic Cancer With Early Detection Tool Via News Direct Topics Artificial Intelligence Exposures Artificial Intelligence Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert September 04, 2024 PancAlert is a Next-Generation Pancreatic Cancer Detection Test in Mainz Biomed’s Research and Development Pipeline – Promising Results of First Analysis From Mainz BioMed NV Via GlobeNewswire Early Cancer Detection Saves Lives - This Biotech Has A Promising New Test September 03, 2024 Early Cancer Detection Saves Lives - This Biotech Has A Promising New Test Via News Direct Mainz Biomed Seeks FDA Approval For Colorectal Cancer Test It Says Is Nearly Twice As Sensitive As Others – A Look At Pipeline And Milestones September 03, 2024 Mainz Biomed Seeks FDA Approval For Colorectal Cancer Test It Says Is Nearly Twice As Sensitive As Others – A Look At Pipeline And Milestones Via News Direct Exposures Product Safety Mainz Biomed's (NASDAQ: MYNZ) Cutting-Edge Colorectal Cancer Test Applies For FDA Breakthrough Status July 31, 2024 Mainz Biomed's (NASDAQ: MYNZ) Cutting-Edge Colorectal Cancer Test Applies For FDA Breakthrough Status Via News Direct Topics Artificial Intelligence Exposures Artificial Intelligence Product Safety Pfizer Records First Sales Growth In Its Post-Covid Era And It Owes It To Cancer July 30, 2024 The market for vaccines and treatments used in managing COVID-19 has shrunk by billions of dollars a year. Forced to rebuild their business, pharmaceutical companies like Pfizer Inc (NYSE: PFE)... Via Benzinga Exposures COVID-19 Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience July 25, 2024 From Mainz BioMed NV Via GlobeNewswire Pfizer And Mainz Provide Examples Of Using Emerging Technology For Good July 10, 2024 This week, Pfizer Inc (NYSE: PFE) revealed a new collaboration to unlock new therapeutic approaches. Its smaller European industry peer specialized in early detection of cancer, Mainz Biomed N.V. Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday July 09, 2024 It's time to start the day with a breakdown of the biggest pre-market stock movers traders need to know about on Tuesday morning! Via InvestorPlace Why Mainz Biomed Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket July 09, 2024 Via Benzinga Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test July 09, 2024 From Mainz BioMed NV Via GlobeNewswire Why Arhaus Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session July 08, 2024 Via Benzinga mRNA Technology Promises To Make A Long-Time Coming Turning Point In Cancer Treatment July 02, 2024 The medical and pharmaceutical community continues to embrace emerging technologies, beginning with mRNA that rose to fame during the COVID-19 pandemic. The beauty of mRNA technology is that it opens... Via Benzinga Exposures COVID-19 Mainz Biomed Provides Half Year 2024 Corporate Update July 02, 2024 Industry Leading Clinical Data Position the Company for FDA Premarket Approval Study From Mainz BioMed NV Via GlobeNewswire Beating Cancer Is Still An Everything-But-Easy Challenge That Pharmaceutical Companies Cannot Solve Overnight June 26, 2024 On Tuesday, Merck Group revealed an unexpected decision to end a Phase III trial of its cancer drug Xevinapant. This move threatens to undermine confidence the research abilities of the Darmstadt,... Via Benzinga Mainz Biomed’s ColoAlert Potentially Puts It On A Similar Track As Big Name Cancer Screening Stocks June 21, 2024 Mainz Biomed’s ColoAlert Potentially Puts It On A Similar Track As Big Name Cancer Screening Stocks Via News Direct Mainz Biomed (NASDAQ: MYNZ) Announces Positive Topline Results From Cancer Detection Studies, Including 92% Sensitivity Rate June 05, 2024 Mainz Biomed (NASDAQ: MYNZ) Announces Positive Topline Results From Cancer Detection Studies, Including 92% Sensitivity Rate Via News Direct Promising Trial Results Show New Standards In Cancer Treatment And Diagnostics Are On The Horizon June 04, 2024 On Friday, Pfizer Inc (NYSE: PFE) revealed its drug for an advanced form of lung cancer showed promising long-term results in a late-stage trial. On Monday, Moderna (NASDAQ: MRNA) and Merck & Co... Via Benzinga 12 Health Care Stocks Moving In Tuesday's Pre-Market Session June 04, 2024 Via Benzinga Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024 June 03, 2024 From Mainz BioMed NV Via GlobeNewswire Mainz Biomed Reports Results of 2024 Annual General Meeting May 31, 2024 From Mainz BioMed NV Via GlobeNewswire Why Ooma Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket May 29, 2024 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday May 29, 2024 It's time to start the day with a breakdown of the biggest pre-market stock movers traders are going to want to watch on Wednesday morning! Via InvestorPlace Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting May 28, 2024 From Mainz BioMed NV Via GlobeNewswire Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial May 20, 2024 From Mainz BioMed NV Via GlobeNewswire Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday May 17, 2024 The final day of trading this week is here and we have the biggest pre-market stock movers worth watching on Friday morning! Via InvestorPlace Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game May 16, 2024 On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will be investing a total of nearly $1 billion in their operations in France,... Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.